文献速递泌尿系结石前列腺增生与排尿功能障碍男科与性医学

泌尿外科临床试验的早期终止、结果报告与发表情况:2007-2019年ClinicalTrials.gov注册分析

Clinical Trial Outcomes in Urology: Assessing Early Discontinuation, Results Reporting and Publication in ClinicalTrials.Gov Registrations 2007-2019.
PubMed 文献 · J Urol · 2020-10-20

该研究评估了2007至2019年ClinicalTrials.gov上泌尿外科临床试验的早期终止、注册结果报告及发表情况,并按申办方和亚专业分析。8,636项试验中41.0%完成、11.6%终止;完成试验中26.9%报告结果、21.6%发表。政府资助试验表现最佳,产业和学术资助分别在完成和结果报告方面滞后。

要点

  • 政府资助试验较产业更少早期终止,且更可能报告和发表结果。
  • 学术资助试验较产业更少早期终止,但结果报告率更低、发表率更高。
  • 亚专业影响较小,但腔内泌尿外科更易早期终止,男科发表率更低。

核心结论

  • 申办方类型与试验完成及成果传播显著相关,政府资助试验表现最佳。
  • 产业和学术资助试验分别在完成和结果报告方面滞后,泌尿外科试验缺乏传播仍是问题。

研究设计与样本

  • 基于ClinicalTrials.gov 2007至2019年注册试验及PubMed/MEDLINE发表数据的回顾性分析。
  • 共纳入8,636项泌尿外科试验,评估早期终止、注册结果报告和发表情况。
  • 采用Cox比例风险模型分析早期终止,逻辑回归分析完成3年后的结果报告或发表。

主要发现

  • 8,636项试验中3,541项(41.0%)完成,999项(11.6%)终止。
  • 完成试验中26.9%报告结果,21.6%发表。
  • 申办方包括学术机构(53.1%)、产业(37.1%)和美国政府(9.8%)。
  • 学术资助试验较产业更少早期终止(校正HR 0.81,95%CI 0.69-0.96,p=0.012)。
  • 政府资助试验较产业更少早期终止(校正HR 0.62,95%CI 0.49-0.78,p<0.001)。

关键数值与推荐

  • 政府资助试验更可能报告结果(校正OR 1.72,95%CI 1.17-2.54,p=0.006)和发表(校正OR 1.89,95%CI 1.23-2.89,p=0.004)。
  • 学术资助试验更不可能报告结果(校正OR 0.65,95%CI 0.48-0.88,p=0.006),但更可能发表(校正OR 1.72,95%CI 1.25-2.37,p<0.001)。
  • 腔内泌尿外科更可能早期终止(校正HR 2.00,95%CI 1.53-2.95,p<0.001)。
  • 普通泌尿外科更可能报告结果(校正OR 1.54,95%CI 1.13-2.11,p=0.006)。
  • 男科更不可能发表(校正OR 0.53,95%CI 0.35-0.81,p=0.003)。

临床怎么用

  • 选择试验申办方时可参考其完成与报告表现,政府资助试验传播最佳。
  • 学术资助试验需加强结果报告,产业资助试验需关注完成率。
  • 腔内泌尿外科试验应关注早期终止风险,男科试验需改善发表率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Clinical trials require significant resources, but benefits are only realized after trial completion and dissemination of results. We comprehensively assessed early discontinuation, registry results reporting, and publication by trial sponsor and subspecialty in urology trials. MATERIALS AND METHODS: We assessed trial registrations from 2007 to 2019 on ClinicalTrials.gov and publication data from PubMed®/MEDLINE®. Associations between sponsor or subspecialty with early discontinuation were assessed using Cox proportional hazards and results reporting or publication with logistic regression at 3 years after completion. RESULTS: Of 8,636 trials 3,541 (41.0%) were completed and 999 (11.6%) were discontinued. Of completed trials 26.9% reported results and 21.6% were published. Sponsors included academic institutions (53.1%), industry (37.1%) and the U.S. government (9.8%). Academic-sponsored (adjusted HR 0.81, 95% CI 0.69-0.96, p=0.012) and government-sponsored trials (adjusted HR 0.62, 95% CI 0.49-0.78, p <0.001) were less likely than industry to discontinue early. Government-sponsored trials were more likely to report (adjusted OR 1.72, 95% CI 1.17-2.54, p=0.006) and publish (adjusted OR 1.89, 95% CI 1.23-2.89, p=0.004). Academic-sponsored trials were less likely to report (adjusted OR 0.65, CI:0.48-0.88, p=0.006) but more likely to publish (adjusted OR 1.72, 95% CI 1.25-2.37, p <0.001). These outcomes were similar across subspecialties. However, endourology was more likely to discontinue early (adjusted HR 2.00, 95% CI 1.53-2.95, p <0.001), general urology was more likely to report results (adjusted OR 1.54, 95% CI 1.13-2.11, p=0.006) and andrology was less likely to publish (adjusted OR 0.53, 95% CI 0.35-0.81, p=0.003). CONCLUSIONS: Sponsor type is significantly associated with trial completion and dissemination. Government-sponsored trials had the best performance, while industry and academic-sponsored trials lagged in completion and results reporting, respectively. Subspecialty played a lesser role. Lack of dissemination remains a problem for urology trials.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Magnani CJ, Steinberg JR, Harmange CI, et al. Clinical Trial Outcomes in Urology: Assessing Early Discontinuation, Results Reporting and Publication in ClinicalTrials.Gov Registrations 2007-2019. J Urol. 2020. PMID: 33079618. doi:10.1097/JU.0000000000001432

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。